PRKX and nasopharyngeal carcinoma: Conversely, reducing FOLR1 levels alters key apoptotic and MAPK pathway genes (BIRC3, caspases, FOS, DUSP1, PRKX, TNFRSF10A), sensitizing taxol-resistant nasopharyngeal carcinoma cells to chemotherapy [112].